Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Investor Day (March 2022)
16 slides from Satellos Bioscience's investor day presentation, Mar 13, 2022

Slide 1: Satellos Bioscience Inc. - Rebuilding muscle from within
March 13, 2022 SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM TSX: MSCL.V 1 OTC: MSCLF

Slide 2: Legal Disclaimers
2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor

Slide 3: Satellos: Restoring regeneration in muscle disorders
3 Satellos: Restoring regeneration in muscle disorders Scientific leaders Massive opportunity Muscle is a regenerative organ Experts in muscle stem cells and Span genetic disorders to ageing role in regeneration conditions to specialty markets Discovered polarity deficits Musculoskeletal dis

Slide 4: Satellos Strategic Path
4 Initial focus on Duchenne SATELLOS Disease modifying therapeutic approach Massive need, limited options and high value Strategic Path Compelling third-party evidence for Satellos approach Extend to other dystrophies/indications Dystrophies associated with the DAPC Cachexia and ageing

Slide 5: Satellos scientific founder: Thought leader in muscle stem cells and regeneration
5 Satellos scientific founder: Thought leader in muscle stem cells and regeneration Muscle stem cells identified Muscle loss in Duchenne and characterized linked to stem cells 2000 2009 2013 2016 Dr. Michael Rudnicki Continuous record of defining stem cell regulation and regenerative processes Ottaw

Slide 6: Duchenne discovery: Stem cell division process perturbed, impairing regeneration
6 Duchenne discovery: Stem cell division process perturbed, impairing regeneration Muscle stem cell Regeneration Requires Balance Balance Perturbed in Duchenne Impairment Tendon Stem cell dividing Stem cell dividing X Progenitor deficit Muscle stem cells Muscle progenitors Pax7+/Myf5- multipotent su

Slide 7: Mechanistic discovery: Loss of polarity impairs stem cell division process
7 Mechanistic discovery: Loss of polarity impairs stem cell division process Healthy Polarity Regeneration Regeneration Duchenne Polarity Occurs Deficit 210-12 Progenitor (Differentiation) Stem cell Stem cell (Self-renewal) Stem cell How is Satellos proposing to address this issue? 7

Slide 8: Our solution in Duchenne: Enabling regeneration by modulating stem cell polarity
8 Our solution in Duchenne: Enabling regeneration by modulating stem cell polarity Duchenne Satellos Solution Satellos Drug Persistent damage signal triggers stem cell divisions polarity to enable regeneration Stem cell dividing Stem cell dividing Impaired stem cell polarity disrupts regeneration Su

Slide 9: Satellos Proof of Concept: Targeting stem cell polarity improves outcomes in Mdx model
9 Satellos Proof of Concept: Targeting stem cell polarity improves outcomes in Mdx model Mdx Enhanced Muscle Quality Q: Can divisions be reset? Mouse Larger muscle Stem cells imbalanced Less fibrosis (green) Larger fibers (black) X Untreated Treated Diaphragm Enhanced Muscle Performance A: Yes

Slide 10: Third party evidence: Regeneration cited as modifier in muscular dystrophy dogs
10 Third party evidence: Regeneration cited as modifier in muscular dystrophy dogs Jagged-1 Rescues the Duchenne Dystrophy Phenotype Colony of dystrophin deficient dogs Normal lifespan possible Near normal muscle function possible Mutation mapped to Jagged1 Precise MOA not elucidated Vieir

Slide 11: Third party evidence: Group at Nationwide identifies polarity as potential disease modifier
11 Third party evidence: Group at Nationwide identifies polarity as potential disease modifier Some boys continue to walk more than 10 years longer than peers Analyzed 419 dystrophin null boys for factors associated with ambulation Snp linked to stem cell polarity (via PARD6G) identified as powe

Slide 12: Near term priorities to support our goal of entering the clinic in 2023
12 Near term priorities to support our goal of entering the clinic in 2023 2022 Q1 Q2 Q3 Q4 Output: Multiple candidates suitable for Proof Design / advance drug candidates and file IP of Concept (POC) testing and optimization Evaluate / select lead drug candidates Pre-IND Studies Utility: Precedent

Slide 13: Leadership
13 Leadership Frank Gleeson, MBA Michael Rudnicki, PhD, OC, FRS Sridhar Narayan, PhD, MBA Geoffrey Mackay Adam Mostafa William Jarosz, JD Board Member and CEO Chief Scientific Officer VP – Drug Discovery Chair — Board of Directors Board Member and Chair – Board Member and CEO – Audit Committee AmpB

Slide 14: Broad Intellectual Property
14 Issued SATELLOS Multiple issued patents related to polarity modulator Wnt7a and its method of use in treating degenerative muscle diseases Broad Intellectual In process/Pending Property Multiple mechanistic patent filings surrounding the regulation of polarity via modulating specific pathways

Slide 15: Competitive differentiation: Only Satellos is focused on restoring regeneration
15 Competitive differentiation: Only Satellos is focused on restoring regeneration Current approaches not Duchenne patient journey focused on regeneration Gene correction ~1 in 3,500 male births Dystrophin gene mutated Muscle Heart inflammation function Target existing fibers Muscle Energy/ fibr

Slide 16: Summary
16 Restoring regeneration may bypass need for Dystrophin in skeletal muscle Summary Targeting polarity provides avenue to restore regeneration Strong rationale as a disease modifying approach Satellos Bioscience Inc. 65 Front Street East, Suite 201 | Toronto, ON M5E 1B5 647-660-1780 | info@sat
Source: Internet Archive copy of satellos.com
More decks from Satellos Bioscience Inc
Corporate Update (November 2026)17 slides · Nov 6, 2026
Corporate Update (July 2026)14 slides · Jul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor Conference23 slides · April 2026
Technical Presentation (February 2026)52 slides · Feb 24, 2026
Investor Presentation (February 2026)21 slides · February 2026
Investor Presentation (October 2025)19 slides · October 2025